Investors
News
Subscribe
Hit enter to search or ESC to close
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Cardiovascular Disease
Metabolic Disease
Liver Disease
Arthritis
Aging
Coronavirus Disease 2019 (COVID-19)
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact Us
All SEC Filings
Investor Relations
Investors
Overview
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
Company Info
Profile
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
Filing Type:
View All
10-K
10-Q
10-Q/A
15-15D
3
4
424B3
8-K
8-K/A
CORRESP
CT ORDER
D
D/A
EFFECT
NT 10-K
NT 10-Q
POS AM
RW
S-1
S-1/A
S-4
S-4/A
SC 13G
SC TO-I
SC TO-I/A
UPLOAD
Year:
View All
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Date
Form
Description
PDF
XBRL
Pages
09/16/13
10-Q
Quarterly report pursuant to sections 13 or 15(d)
Documents
EX-31.1
EX-32.1
26
07/30/13
8-K
Current report filing
3
06/17/13
D
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
5
06/06/13
10-K
Annual report pursuant to section 13 and 15(d)
Documents
EX-31.1
EX-32.1
51
02/11/13
10-Q
Quarterly report pursuant to sections 13 or 15(d)
Documents
EX-31.1
EX-32.1
26
11/13/12
10-Q
Quarterly report pursuant to sections 13 or 15(d)
Documents
EX-31.1
EX-32.1
26
08/30/12
EFFECT
Notice of Effectiveness
1
08/28/12
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
08/23/12
S-1/A
General form of registration statement for all companies including face-amount certificate companies
67
08/22/12
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
11
12
13
14
15
16
17
18
19
20
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Investor Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Contact Us
Investors
News
Subscribe